Evaluation of HIV-1 ambiguous nucleotide frequency during antiretroviral treatment interruption

Journal of Acquired Immune Deficiency Syndromes

Volumn 61, Issue 1, 2012, Pages 19-22

  Li, Jonathan Z ^a   Christensen, Julie A ^a,b   Wang, Hongying ^c   Spritzler, John ^c   Kuritzkes, Daniel R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b OBERLIN COLLEGE   (United States)

^c CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

Author keywords

ambiguous nucleotides; diversity; therapeutic vaccination; treatment interruption

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NUCLEOTIDE; PLACEBO; RNA DIRECTED DNA POLYMERASE;

ANALYSIS; ANALYTIC TREATMENT INTERRUPTION; ARTICLE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; TREATMENT OUTCOME; VIREMIA;

AIDS VACCINES; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VARIATION; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTHERAPY; MOLECULAR SEQUENCE DATA; PLACEBOS; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; SEQUENCE ANALYSIS, DNA; WITHHOLDING TREATMENT;

EID: 84865778158     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318264460f     Document Type: Article

References (10)

1. Kouyos RD, von Wyl V, Yerly S, et al. Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection. Clin Infect Dis. 2011;52:532-539.
2. Schooley RT, Spritzler J, Wang H, et al. AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J Infect Dis. 2010;202:705-716.
3. Kearney M, Maldarelli F, Shao W, et al. Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J Virol. 2009;83:2715-2727.
4. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA. 2008;105:7552-7557.
5. Yerly S, Gunthard HF, Fagard C, et al. Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions. AIDS. 2004;18:1951-1953.
6. Joos B, Fischer M, Kuster H, et al. HIV rebounds from latently infected cells, rather than from continuing low-level replication. Proc Natl Acad Sci USA. 2008;105:16725-16730.
7. Shankarappa R, Margolick JB, Gange SJ, et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol. 1999;73:10489-10502.
8. Delwart EL, Pan H, Sheppard HW, et al. Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. J Virol. 1997;71:7498-7508.
9. Arien KK, Vanham G, Arts EJ. Is HIV-1 evolving to a less virulent form in humans? Nat Rev Microbiol. 2007;5:141-151.
10. Brumme ZL, John M, Carlson JM, et al. HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One. 2009;4:e6687.